Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE
The United Arab Emirates becomes the second country to offer the pill after the drugmaker launched it in the U.S. in early January.
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk uses AI to fast-track drug launches, expand India role
Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming obesity drugs market.
European medicines regulator recommends approval for Novo's Wegovy pill
The European Medicines Agency recommended approval for Novo Nordisk's weight-loss pill Wegovy, the regulator said on Friday, clearing its path to become the first oral weight loss drug in Europe, ahead of U.S. rival Eli Lilly.
Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy pill reaching approximately 137,000 total prescriptions in its 18th week on the US market, a 4% decline week on week.
Novo Nordisk's next obesity battlefront: Winning beyond America
Novo Nordisk sees a "major opportunity" outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs. The battle for dominance over the lucrative market has so far focused largely on the key U.S. market, currently accounting for more than half of both Novo's and Eli Lilly's respective sales.
Novo Nordisk: The First Fruits Of Labor
Novo Nordisk has had a stellar past month at the stock markets with a 25% rise after it touched multi-year lows earlier this year. Fuelling the rise are oral Ozempic and Wegovy pill launches, alongside FDA approvals and telehealth collaborations. The company even managed to trivially raise sales guidance. With low market multiples, I retain a Buy rating as the company's restructuring efforts are beginning to bear fruit.
Novo Nordisk A/S Q1 Earnings Call Highlights
Novo Nordisk A/S NYSE: NVO said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight
The company said the majority of the weight loss—around 84%—came from losing body fat while preserving muscle function and improving muscle health.
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
